Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Sharp revenue increase and strong progress in research programs for Galapagos in the first half-year 2007
August 27th, 2007
Galapagos NV (Euronext & LSE: GLPG), an integrated drug discovery company, announces its half year results and reiterates guidance for the second half of 2007. Galapagos' operational and strategic highlights for first half of 2007 include: * Drug Discovery division reached striking results in its proprietary therapeutic programs; new and strong data in animal tests in the arthritis programs bode well for initiating phase I clinical studies in 2008 * Rodent studies showed that the SARM1 and OARA2 compounds against osteoporosis increase bone strength to a higher level than bisphosphonates, the drugs currently marketed for...
Source: Clinical Trials Week (2007-08-27)
|
